#United States #New York #Gross Law Firm #Eylea #Regeneron

Regeneron Pharmaceuticals Sued: A Call to Action for Shareholders

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has recently found itself at the center of a legal controversy, facing a class-action lawsuit for purported violations of securities laws. This development comes as the Gross Law Firm has reached out to shareholders to alert them to potential implications and actions they can take.

The Basis of the Lawsuit

The lawsuit stems from allegations that during the class period, from November 2, 2023, to October 30, 2024, Regeneron issued false statements and failed to disclose critical information regarding its pricing practices for its well-known product, Eylea. The complaint notes several key points:

1. Credit Card Fee Payments: Regeneron allegedly paid distributors to ensure that they would not charge Eylea customers higher prices when using credit cards. These payments effectively subsidized customer prices associated with credit card transactions.
2. Price Concessions: These financial maneuvers granted Regeneron a competitive edge in pricing, allowing them to misrepresent the true selling prices for Eylea.
3. Inflated Sales Figures: By obscuring these price concessions, Regeneron allegedly inflated its reported sales figures for Eylea, misleading stakeholders about the company's performance.
4. False Claims Act Violations: Failing to accurately report its credit card fee payments is said to have resulted in an overstatement of the Average Sales Price (ASP) of Eylea, thus violating federal regulations outlined in the False Claims Act.

These allegations suggest that Regeneron misled the public regarding its financial health and business strategy, leading to potentially significant repercussions for investors.

Important Deadlines for Shareholders

For shareholders who acquired REGN shares during the aforementioned period, time is of the essence. The Gross Law Firm has established a deadline of March 10, 2025, for registering to participate in this class action. Those interested can begin the process by visiting the Gross Law Firm’s website to submit their information.

By registering, shareholders will not only be included in the potential recovery process but will also gain access to monitoring software that provides updates and insights throughout the litigation's duration.

Why This Matters

The circumstances surrounding the lawsuit highlight critical issues regarding corporate accountability and investor rights. The Gross Law Firm is dedicated to protecting the interests of shareholders, ensuring that those who have suffered losses due to fraudulent practices are able to seek a remedy.

Furthermore, this legal matter underscores the importance of transparency in financial reporting and adherence to ethical business practices. As Regeneron navigates this tumultuous period, investors must remain vigilant and proactive.

In conclusion, shareholders of Regeneron Pharmaceuticals, Inc. are urged to act swiftly. The ongoing lawsuit serves as a stark reminder of the need for corporate integrity and the protection of investor interests. Don’t delay—register now to safeguard your rights as a shareholder.

For further information or to register, please contact the Gross Law Firm directly or visit their website. Remember, there is no cost or obligation to participate, making this an accessible opportunity to potentially recover losses incurred during the class period.

• ---

Contact Details for The Gross Law Firm:
15 West 38th Street, 12th floor, New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

Stay informed and take part in protecting your rights as an investor.